FDA Approved: ELAHERE — Original Application (ImmunoGen, Inc.)

View source ↗

Summary

The FDA approved ELAHERE (mirvetuximab soravtansine) from ImmunoGen as the original approval for FRα-positive, platinum-resistant epithelial ovarian cancer, inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

ORIG AP for ELAHERE (MIRVETUXIMAB SORAVTANSINE)